Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Cariani, Elisabetta ^a   Pilli, Massimo ^b   Zerbini, Alessandro ^c   Rota, Cristina ^a   Olivani, Andrea ^b   Pelosi, Guido ^b   Schianchi, Claudia ^b   Soliani, Paolo ^d   Campanini, Nicoletta ^e   Silini, Enrico Maria ^e   Trenti, Tommaso ^a   Ferrari, Carlo ^b   Missale, Gabriele ^b  

^a Nuovo Ospedale S Agostino   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPHOCYTIC INFILTRATION; MALE; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; ONCOGENE; OVERALL SURVIVAL; PHENOTYPE; PREVALENCE; PROGRAMMED DEATH LIGAND 1 GENE; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; UPREGULATION; CD8+ T LYMPHOCYTE; CELL LINEAGE; CYTOLOGY; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LIVER; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINEAGE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PHENOTYPE; RECURRENCE; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84857743064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032493     Document Type: Article

References (33)

1. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
2. Thorgeirsson SS, Lee JS, Grisham JW, (2006) Molecular prognostication of liver cancer: end of the beginning. J Hepatol 44: 798-805.
3. Budhu A, Forgues M, Ye Q-H, Jia HL, He P, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111.
4. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
5. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, et al. (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68: 6779-6788.
6. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392.
7. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667-676.
8. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, et al. (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12: 410-416.
9. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, et al. (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52.
10. Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, et al. (2004) Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64: 6058-6064.
11. Sakai Y, Honda M, Fujinaga H, Tatsumi I, Mizukoshi E, et al. (2008) Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients. Cancer Res 68: 10267-10279.
12. Chew V, Tow C, Teo M, Wong HL, Chan J, et al. (2010) Inflammatory tumor microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 52: 370-379.
13. Disis ML, (2010) Immune regulation of cancer. J Clin Oncol 28: 4531-4538.
14. Budhu A, Wang XW, (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80: 1197-1213.
15. Li J, Lau GK, Chen L, Dong SS, Lan HY, et al. (2011) Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One 6 (7): e21816 Epub 2011 Jul 7.
16. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. (2005) Effector memory T-cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.
17. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
18. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M, (1998) Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27: 407-414.
19. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, et al. (2006) Tumor lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 45: 246-253.
20. Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, et al. (2009) Profile of tumor antigen-specific CD8 T-cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137: 682-690.
21. Shi F, Shi M, Zeng Z, Qi R-Z, Liu Z-W, et al. (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128: 887-896.
22. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, et al. (2009) Overexpression of PDL1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971-979.
23. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, et al. (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of regulatory T-cells. Hepatology 41: 722-730.
24. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, et al. (2006) Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45: 254-262.
25. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al. (2007) FOXP3+ regulatory T-cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13: 902-911.
26. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. (2007) Increased regulatory T-cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132: 2328-2339.
27. Zhou J, Tong D, Pan W, Zhu L-Y, Li L, et al. (2009) Increased intratumoral regulatory T-cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 125: 1640-1648.
28. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. (2007) Intratumoral balance of regulatory and cytotoxic T-cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593.
29. Wilke CM, Wu K, Zhao E, Wang G, Zou W, (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127: 748-758.
30. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, et al. (2008) EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68: 1451-1461.
31. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, et al. (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16: 4688-4694.
32. Mareel M, Leroy A, (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83: 337-376.
33. Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, et al. (2009) Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT-cells in intrahepatic malignant tumors. J Immunol 182: 5140-5151.